CBD shows promise for treating some medical conditions but the potential for interactions with other drugs is a cause for concern, as is poor quality control, according to a recent review of science in the field ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.